StockData
INBPOTCPharmaceutical PreparationsFiscal year ends June 30

INTEGRATED BIOPHARMA INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$5.59M
P/E (TTM)
–
Dividend yield
–

About Integrated Biopharma

Pharmaceutical Preparations, SIC 2834

Integrated BioPharma, Inc. manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products. The company operates primarily through two segments: Contract Manufacturing and Other Business Lines. Contract Manufacturing produces dietary supplements for distributors, multilevel marketing firms, and specialized health-care providers. The Other Business Lines segment provides warehousing and order fulfillment services while distributing select raw materials. Its customer base is situated mainly in the United States and Luxembourg, with significant business generated from major contract manufacturing accounts.

The company operates its corporate executive offices in Hillside, New Jersey. Its manufacturing and commercial operations are supported by domestic infrastructure, including leased warehouse facilities and equipment, to supply its business partners across its primary geographic markets in the United States and abroad.

Summary of the business section of Integrated Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
INTEGRATED BIOPHARMA INC
Founded
1995
Headquarters
Hillside, NJ
Address
225 Long Avenue, Building 15 07205
Phone
(973) 926-0816
Employees
134, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
CBIZ CPAs P.C., Morristown, New Jersey

Stock & identifiers

Ticker
INBP
Exchange
OTC
IPO date
Oct 30, 1996
Shares outstanding
31M, Sep 23, 2026
Public float
$3.43M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1016504
CUSIP
45811V105
ISIN
US45811V1052
EIN
22-2407475

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christina KayCo-Chief Executive Officer, Director4,883,979
Sheppard RivaCo-Chief Executive Officer4,899,679
Dina MasiChief Financial Officer347,200
Robert CanarickDirector234,233
William H. MilmoeDirector2,512,751
Damon DeSantisDirector10,497,641
Eric J. FriedmanDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$325.04K$318.64K$334.58K$72–
FY2024$331.30K$315.19K$343.72K$42–
FY2023$306.74K$296.14K$330.79K$66–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of September 23, 2026, we had approximately 134 full-time employees, including 99 who are members of the local unit of the Teamsters Union and are covered by a collective bargaining agreement which expires on September 30, 2026.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 24, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 24, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 16, 2016Late filingNotification of late filing
Feb 14, 2013Late filingNotification of late filing
Nov 14, 2012Late filingNotification of late filing
Sep 28, 2012Late filingNotification of late filing
May 16, 2012Late filingNotification of late filing
Feb 14, 2012Late filingNotification of late filing
Nov 14, 2011Late filingNotification of late filing
Sep 28, 2011Late filingNotification of late filing
May 16, 2011Late filingNotification of late filing
May 17, 2010Late filingNotification of late filing
Nov 16, 2009Late filingNotification of late filing
Nov 2, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 28, 2009Late filingNotification of late filing
May 15, 2009Late filingNotification of late filing
Apr 13, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 13, 2009DelistingNotice of delisting from exchange (Form 25)
Mar 24, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 17, 2009Late filingNotification of late filing
Sep 29, 2008Late filingNotification of late filing
May 16, 2008Late filingNotification of late filing
Apr 25, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 14, 2008Late filingNotification of late filing
Nov 15, 2007Late filingNotification of late filing
Feb 5, 2007DelistingNotice of delisting from exchange (Form 25)
Feb 5, 2007ListingRegistration of securities on an exchange (Form 8-A)
Jan 24, 2007Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 16, 2003Name changeName changed from INTEGRATED HEALTH TECHNOLOGIES INC to INTEGRATED BIOPHARMA INC
Apr 15, 2003ListingRegistration of securities on an exchange (Form 8-A)